Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective historically controlled study of pediatric nifurtimox in Chagas disease
2022-001504-17Phase 3
- Sponsor
- Bayer
- Start
- Apr 2022
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of nifurtimox in American trypanosomiasis (CD) (2 arms), sponsored by Bayer. Primary endpoint: Primary: Percentage of subjects with seroreduction or seroconversion at 12-month follow-up.
02
Drugs
nifurtimox
03
Conditions
American trypanosomiasis (CD)
Beyond the preview
Go deeper on 2022-001504-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001504-17.